19 patents
Utility
Coversin for the Treatment of Autoimmune Blistering Diseases
11 Jan 24
The present invention relates to methods of treating or preventing AIBD.
Miles Nunn, Brihad Abhyankar, Christian David Sadik
Filed: 9 Jun 23
Utility
Coversin (OmCI) for the treatment of autoimmune blistering diseases: bullous pemphigoid (BP) and epidermolysis bullosa acquisita (EBA)
22 Aug 23
The present invention relates to methods of treating or preventing AIBD.
Miles Andrew Nunn, Brihad Abhyankar, Christian David Sadik
Filed: 20 Apr 18
Utility
Coversin Variants Lacking C5 Binding
5 Jan 23
The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.
Miles Andrew Nunn
Filed: 18 Nov 21
Utility
Method of Treatment
24 Nov 22
The present invention relates to methods of treating or preventing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) in a subject, which comprises administering to the subject a therapeutically or prophylactically effective amount of an agent which is a protein comprising amino acids 19 to 168 of the amino acid sequence in FIG. 2 (SEQ ID NO: 2) or a functional equivalent of this protein.
Wynne H. Weston-Davies, Miles Nunn
Filed: 27 Sep 19
Utility
Method of Inhibiting C5 Cleavage
17 Nov 22
The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways.
Miles Andrew Nunn
Filed: 5 Jan 22
Utility
Subtitle data editing method and subtitle data editing program for contents such as moving images
4 Oct 22
The present invention provides a subtitle data editing method that simplifies the work of inputting subtitles to be displayed on contents such as moving images and facilitates quick and efficient editing work.
Yosuke Yamashita
Filed: 16 Aug 19
Utility
Method of Treating Peripheral Nerve Disorders
11 Aug 22
The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of peripheral nerve disorders.
John Hamer
Filed: 22 Sep 21
Utility
Subtitle Data Editing Method and Subtitle Data Editing Program for Contents Such As Moving Images
26 May 22
The present invention provides a subtitle data editing method that simplifies the work of inputting subtitles to be displayed on contents such as moving images and facilitates quick and efficient editing work.
Yosuke YAMASHITA
Filed: 16 Aug 19
Utility
Coversin for Use in the Treatment of Rheumatic Diseases
17 Feb 22
The present invention relates to methods of treating or preventing rheumatic disease.
Miles Nunn, Andrew Luster, Yoshishige Miyabe
Filed: 10 Sep 19
Utility
Coversin variants lacking C5 binding
4 Jan 22
The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.
Miles Andrew Nunn
Filed: 20 Apr 18
Utility
Ornithodoros Moubata Complement Inhibitor for Use in the treatment of Complement-Mediated Diseases in Patients with C5 Polymorphism
16 Sep 21
Wynne H. Weston-Davies
Filed: 28 May 21
Utility
Method of Treating Respiratory Disorders
12 Aug 21
The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation, and in particular in the treatment of respiratory disorders.
John Hamer
Filed: 29 Apr 21
Utility
Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with C5 polymorphism
6 Jul 21
The present invention relates to methods of treating or preventing a complement-mediated disease and/or disorder in a subject with a complement C5 polymorphism, including administering to a subject in need thereof a therapeutically or prophylactically effective amount of an agent that a) inhibits the classical complement pathway, the alternative complement pathway and the lectin complement pathway; and/or b) inhibits eicosanoid activity.
Wynne H. Weston-Davies
Filed: 8 Jun 15
Utility
Methods For Treatment of Neuropathic Pain
10 Jun 21
Methods of treating neuropathic pain are provided.
Paul Louis Chazot, Miles Andrew Nunn, Ilona Genowefa Obara
Filed: 7 Dec 18
Utility
Coversin for the Treatment of Cicatrising Eye Inflammatory Disorders
22 Apr 21
The present invention provides a method and compositions for treating or preventing a cicatrising eye inflammatory disorder, in particular Sjögren's syndrome, mucous membrane pemphigoid or atopic keratoconjunctivitis.
Wynne H Weston-Davies
Filed: 20 Apr 18
Utility
Coversin Variants Lacking C5 Binding
9 Dec 20
The invention is directed to modified Coversin polypeptides which exhibit leukotriene or hydroxyeicosanoid binding activity and reduced or absent C5 binding relative to the unmodified Coversin polypeptide; to nucleic acid molecules encoding said modified Coversin polypeptides; vectors and host cells comprising said nucleic acid molecules; and methods of treating or preventing diseases or conditions mediated by a leukotriene or hydroxyeicosanoid in a subject comprising administering said modified polypeptides or nucleic acids to a subject.
Miles Andrew Nunn
Filed: 19 Apr 18
Utility
Method of Treating Myasthenia Gravis
9 Sep 20
The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation and in particular in the treatment of myasthenia gravis.
John Hamer, Wynne Weston-Davies
Filed: 24 Oct 19
Utility
EV576 For Use in the Treatment of Viral Infections of the Respiratory Tract
20 May 20
The present invention relates to methods of treating and preventing the inflammatory effects of viral infection of the upper and lower respiratory tracts, including infection by SARS coronovirus (SARS), pandemic Influenza A H5N1 (avian influenza) and pandemic influenza A H1N1 (swine ‘flu).
Wynne Weston-Davies
Filed: 6 Jun 19
Utility
Coversin for the Treatment of Autoimmune Blistering Diseases
15 Apr 20
The present invention relates to methods of treating or preventing AIBD.
Miles Andrew Nunn, Brihad Abhyankar, Christian David Sadik
Filed: 19 Apr 18
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first